IPO registrations (S-1, F-1) · Registrants
AVIGEN INC \DE
- SEC CIK
- 932903 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 1996-05-08, last 1996-11-15; 1 initial registration, 2 amendments
- Outcome
- Final prospectus filed 1996-05-22
- Industry (SIC)
- In Vitro & In Vivo Diagnostic Substances 2835
- Incorporated in
- DE
- Business address
- 1301 HARBOR BAY PARKWAY, ., Alameda, CA 94502
- EIN
- 13-3647119
- EDGAR entity type
- operating
- Insiders and CEO pay
- AVIGEN INC \DE on the corporate pages
Offering terms
- Proposed price range
- $7.00–$9.00 per share (S-1/A filed 1996-05-15)
- Final price
- $8.00 per share, within the range (424B4 filed 1996-05-22, an initial public offering)
- Shares sold
- 2,500,000
- Gross proceeds
- $20,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol AVGN
- Lead underwriters
- Wedbush Securities
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- SEC filer: AVIGEN INC \DE EXACT (CIK (EXACT))
Filings 5
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 1996-05-08 | S-1/A | S-1/A (amendment) | AVIGEN INC \DE | 0000891618-96-000318 ↗ |
| 1996-05-15 | S-1/A | S-1/A (amendment) | AVIGEN INC \DE | 0000891618-96-000468 ↗ |
| 1996-05-22 | S-1MEF | S-1MEF (added securities) | AVIGEN INC \DE | 0000891618-96-000606 ↗ |
| 1996-05-22 | 424B4 | 424B4 (final prospectus) | AVIGEN INC \DE | 0000891618-96-000622 ↗ |
| 1996-11-15 | S-1 | S-1 (registration) | AVIGEN INC \DE | 0000891618-96-002810 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 1996-05-15 | S-1/A | registration statement | $7.00–$9.00 | 2,300,000 | - | Nasdaq AVGN | 2 | from the submission text; range, price sentence, shares headline, proceeds computed, price outside the range dropped, underwriting table 1, cover names 1 | document ↗ | |
| 1996-05-22 | 424B4 | final prospectus | $8.00 | 2,500,000 | $20,000,000 | Nasdaq AVGN | 1 | from the submission text; price sentence, shares headline, proceeds computed, cover names 1 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| SAUTER ANDREW AUGUST | Officer | CEO, President and CFO; Vice President, Finance; VP, Finance | 8 | 2006–2009 | |
| HOROVITZ ZOLA P | Director | 7 | 2006–2009 | ||
| PAULSON THOMAS J | Other | 1 | 2006 | ||
| CHAHINE KENNETH | Director; Director,Officer | Chief Executive Officer | 4 | 2006–2009 | |
| COFFEE MICHAEL DENIS | Officer | Chief Business Officer | 3 | 2006–2007 | |
| Johnson Kirk William | Officer | VP, Preclinical Development; VP Research and Development; VP, Research & Development | 4 | 2006–2009 | |
| MCGUIRE DAWN | Officer | Chief Medical Officer | 2 | 2006 | |
| Thomson Mary Christina | Officer | VP, Corp Counsel & Secretary; VP, Corporate Counsel | 6 | 2006–2007 | |
| IWAKI YUICHI | Director | 6 | 2006–2008 | ||
| Wallace Richard John | Director | 6 | 2006–2009 | ||
| PRENDERGAST JOHN K A | Director | 7 | 2006–2009 | ||
| VAPNEK DANIEL | Director | 1 | 2006 | ||
| DILLY STEPHEN GEORGE | Director | 5 | 2007–2009 | ||
| OHRSTROM JAN K | Director | 5 | 2007–2009 | ||
| BIOTECHNOLOGY VALUE FUND II LP | Other; TenPercentOwnerOther | 9 | 2008–2009 | ||
| BIOTECHNOLOGY VALUE FUND L P | Other; TenPercentOwnerOther | 9 | 2008–2009 | ||
| BVF INC/IL | TenPercentOwner; TenPercentOwnerOther | 9 | 2008–2009 | ||
| BVF INVESTMENTS LLC | Other; TenPercentOwnerOther | 9 | 2008–2009 | ||
| BVF PARTNERS L P/IL | TenPercentOwner; TenPercentOwnerOther | 9 | 2008–2009 | ||
| COPPEDGE ROBERT M | Other | 1 | 2009 | ||
| LAMPERT MARK N | TenPercentOwner | 3 | 2009 | ||
| NODELMAN OLEG | Other | 1 | 2009 | ||
| PERRY MATTHEW D | Other | 1 | 2009 | ||
| BVF Acquisition LLC | Other | 1 | 2009 | ||
| BURLINGAME ASSET MANAGEMENT, LLC | TenPercentOwner | 5 | 2009 | ||
| Golden Howard | TenPercentOwner | 6 | 2009 | ||
| Southpaw Asset Management LP | TenPercentOwner | 6 | 2009 | ||
| Southpaw Credit Opportunity Master Fund, L.P. | TenPercentOwner | 6 | 2009 | ||
| Southpaw Holdings LLC | TenPercentOwner | 6 | 2009 | ||
| Wyman Kevin | TenPercentOwner | 6 | 2009 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| SEC filer | AVIGEN INC \DE | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry In Vitro & In Vivo Diagnostic Substances, CA first:
- ANSYS DIAGNOSTICS INC CA
- Monogram Biosciences, Inc. CA
- ARGONAUT TECHNOLOGIES INC CA
- GENENCOR INTERNATIONAL INC CA
- Intuity Medical, Inc. CA
- Global Wholehealth Partners Corp CA
- Lucira Health, Inc. CA
- Alpha Teknova, Inc. CA
- ALERE SAN DIEGO, INC. CA
- Anbio Biotechnology 2M
In other datasets, the same topic (Health) in CA:
- Nonprofit: 24 HOUR CANCER DANCE-A-THON (Nonprofits (IRS Form 990))
Interests: In Vitro & In Vivo Diagnostic Substances · Health